7 resultados
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification and characterization of an enzyme involved in expression of the cancer phenotype, as well as to the identification and selection of compounds for its inhibition. In particular aspects, the invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification and characterization of an enzyme involved in expression of the cancer phenotype, as well as to the identification and selection of compounds for its inhibition. In particular aspects, the invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification and characterization of an enzyme involved in expression of the cancer phenotype, as well as to the identification and selection of compounds for its inhibition. In particular aspects, the invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification and characterization of an enzyme involved in expression of the cancer phenotype, as well as to the identification and selection of compounds for its inhibition. In particular aspects, the invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the identification and characterization of an enzyme involved in expression of the cancer phenotype, as well as to the identification and selection of compounds for its inhibition. In particular aspects, the invention
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the molecular cloning, purification, characterization and inhibition of farnesyl:protein transferase, an enzyme involved in expression of the cancer phenotype, for example, in the transfer of farnesyl groups to oncogenic
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the molecular cloning, purification, characterization and inhibition of farnesyl:protein transferase, an enzyme involved in expression of the cancer phenotype, for example, in the transfer of farnesyl groups to oncogenic